NCT02310048View on ClinicalTrials.gov

Comparative Oral Bioavailability Study of MT-1303

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

MT-1303-FormA

DRUG

MT-1303-FormB

Trial Locations (1)

Unknown

Investigational site, Leeds

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY